Drugs / Danggui Buxue Tang
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03578575 | Jul 2018 → Jul 2020 | nasopharyngeal carcinoma | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00421564 | Feb 2003 → Dec 2004 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danggui Buxue Tang | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03578575 ↗ |
| Known as | DBT | “We conducted a double-blind, randomized trial to investigate the effect of Danggui Buxue Tang (DBT) in combination with definite CCRT on patients with NPC.” PMID 41158262 ↗ Sep 20251“DBT-Danggui Buxue Tang” NCT00421564 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.” NCT03578575 ↗ |